Shares of LifeMD were higher after Novo Nordisk slashed prices for its GLP-1 obesity drugs for customers who pay out of pocket. The stock rose 5.8% to $4.90 in premarket trading. LifeMD said the lower ...

(Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy, today announced a new, lower cash-pay price for GLP-1 medications, Wegovy ® and Ozempic ®, made possible through its ...

Q3 2025 Earnings Call Transcript November 17, 2025 LifeMD, Inc. misses on earnings expectations. Reported EPS is $-0.1 EPS, ...

Telemedicine is revolutionizing healthcare access, supported by regulatory measures, such as the 1135 waiver and the Coronavirus Preparedness Act, which expanded Medicare coverage for telehealth ...

WW International, Inc. delivered strong Q3, exceeding revenue & EBITDA expectations, driven by its Clinical Business. Learn ...

For a limited time, patients in the US can get the first two doses of authentic, FDA-approved Wegovy(R) and Ozempic(R) for only $199 each beginning November 17, 2025 -- Also effective November 17, ...

LifeMD fell 25% YTD, with nearly 1x 2025 sales, improved Q3 results, and a WorkSimpli divestiture worth up to $50M. See why ...

LifeMD Inc. (NASDAQ: LFMD) shares fell after the company released its third-quarter earnings report after Monday's closing ...

Remedy Meds is an online consumer health and pharmacy platform that provides access to compounded glucagon-like peptide-one ...

The Trump administration is making a significant effort to reduce the cost of weight loss drugs. Its agreement with ...

Starting in January, public workers and retirees enrolled in Group Insurance Commission plans will need to participate in a new program to maintain coverage for GLP-1 prescriptions as ...

Unlike many pharmacies charging more than $1,000 per month for GLP-1 therapies, STL Med Weight Loss offers its program at a ...